106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ASCOLUN07223
Abbreviations
ALK, anaplastic lymphoma kinase; ASCO, American Society of Clinical Oncology; EGFR,
epidermal growth factor; NSCLC, non-small cell lung cancer; OH (CCO), Ontario Health
(Cancer Care Ontario); PD-L1, programmed death ligand 1; PS, performance status; TPS,
Tumor Proportion Score
Source
Singh N, Temin S, Baker, Jr. S, et al. erapy for Stage IV Non-Small Cell Lung Cancer
Without Driver Alterations: ASCO Guideline Update. 2022 July 11. doi: 10.1200/
JCO.22.00825
Hanna NH, Schneider BJ, Temin S, et al. erapy for stage IV non-small cell lung cancer
without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol.
2021 Feb 16. doi: 10.1200/JCO.19.03022
e guideline was a cooperative effort among the American Society of Clinical Oncolog y
and Ontario Health (Cancer Care Ontario).
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and
other clinical tools and resources, is available at www.asco.org/thoracic-cancer-guidelines.
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical
Oncolog y Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is
not intended to substitute for the independent professional judgment of the treating physician.
Practice guidelines do not account for individual variation among patients. is pocket guide
does not purport to suggest any particular course of medical treatment. Use of the practice
guidelines and this resource are voluntary. e practice guidelines and additional information
are available at www.asco.org/thoracic-cancer-guidelines. Copyright © 2022 by American
Society of Clinical Oncolog y. All rights reserved.
